{"meshTags":["Antineoplastic Agents","ras Proteins","Humans","Proto-Oncogene Proteins B-raf","Melanoma","Animals"],"meshMinor":["Antineoplastic Agents","ras Proteins","Humans","Proto-Oncogene Proteins B-raf","Melanoma","Animals"],"publicationTypes":["Comment","Journal Article","Research Support, Non-U.S. Gov\u0027t"],"abstract":"Large-scale, unbiased combinatorial drug screening has been used to identify effective genotype-selective therapeutic combinations that show promising activity in preclinical models of mutant BRAF andRAS melanoma that are resistant to the clinical BRAF inhibitor vemurafenib.","title":"Unpicking the combination lock for mutant BRAF and RAS melanomas.","pubmedId":"23319765"}